ASSENT 3

(redirected from ASSENT III)

ASSENT 3

Assessment of the Safety of a New Thrombolytic-3. A clinical trial comparing the efficacy and safety of tenecteplase plus enoxaparin or abciximab with tenecteplase plus weight-adjusted unfractionated heparin in patients with acute myocardial infarction (MI).
Conclusion Tenecteplase plus enoxaparin or abciximab reduced ischaemic complications of an acute MI; tenecteplase plus enoxaparin may be a reperfusion regimen warranting further study.
References in periodicals archive ?
and Boehringer Ingelheim, completed enrollment in the ASSENT III study of TNKase in combination with various regimens of anti-thrombotic agents for acute myocardial infarction (heart attack).